Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 6/20 | 0.55 |
| ▸ | CA2 | P00918 | 5/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | LPL | P06858 | 3/20 | 0.52 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | F11 | P03951 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204921 | 0.83 | ENPP2 (0.73) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL18394607 | 0.73 | CA2 (0.78) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL13667445 | 0.73 | CA2 (0.78) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL806835 | 0.73 | CA2 (0.78) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL17698481 | 0.73 | TRPV6 (0.70) | ENPP2CA2CA1CA4CA6 | |
| SCHEMBL29262949 | 0.71 | CA2 (0.74) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL8912 | 0.71 | ENPP2 (1.00) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL28607440 | 0.71 | ENPP2 (0.50) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL147275 | 0.71 | — | — | |
| SCHEMBL39239 | 0.69 | KDM4E (0.58) | ENPP2CA2CA1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 790 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3606528-B1 | TRICYCLIC COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS AND USES THEREOF | BROAD INST INC (US) | 2023-10-18 | — | — | EP | claimed |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-06-23 | — | — | US | claimed |
| EP-3172213-B1 | MACROCYCLIC KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-09-22 | — | — | EP | claimed |
| EP-3558985-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-10-30 | — | — | EP | claimed |
| EP-3068405-B1 | PYRROLO [1,2,F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2019-05-01 | — | — | EP | claimed |
| WO-2018119266-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | claimed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | claimed |
| US-9493469-B2 | Piperidine inhibitors of Janus kinase 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | claimed |
| EP-2177522-B1 | NOVEL CARBAPENEM DERIVATIVES | XUANZHU PHARMA CO LTD (CN) | 2013-09-04 | — | — | EP | claimed |
| EP-1631570-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | Abbott Laboratories (US) | 2006-03-08 | — | — | EP | claimed |
| WO-2004083207-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ABBOTT LABORATORIES (US) | 2004-09-30 | — | — | WO | claimed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | claimed |
| US-5837873-A | PROTECTED OXYDIAMINES | ABBOTT LABORATORIES (US) | 1998-11-17 | — | — | US | claimed |
| US-11999757-B2 | Synthesis of boronate ester derivatives and uses thereof | MELINTA SUBSIDIARY CORP. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-117986153-A | Ionizable cationic lipid compound, and preparation method and application thereof | 晟迪生物医药(苏州)有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-4356736-A2 | SYNTHESIS OF BORONATE SALTS | Melinta Therapeutics, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| US-5494666-A | BETA-LACTAMASE INHIBITORS, ANTIBACTERIALS | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | disclosed |
| US-5464617-A | 1H-2,6a-diazacyclobut(cd)indene-6-carboxylic acid derivatives, antibiotics | HOFFMANN-LA ROCHE INC. (US) | 1995-11-07 | — | — | US | disclosed |
| CN-1100415-A | New preparation process for sulphurated derivatives of imidazole and the new intermediates obtained | ROUSSEL UCLAF (FR) | 1995-03-22 | — | — | CN | disclosed |
| EP-0620225-A1 | Cephalosporin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1994-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | ENPP2 191/4885CA2 4677/4885CA1 4089/4885 |
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | ENPP2 2518/4885CA2 3109/4885CA1 2600/4885 |
| US-11999757-B2 | Synthesis of boronate ester derivatives and uses thereof | ADH5, ADH1A, ADH7 | ENPP2 4682/4885CA2 1540/4885CA1 1463/4885 |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | ENPP2 191/4885CA2 4677/4885CA1 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.